ALX Oncology
Sarah Bolton is a Research and Development Scientist at ALX Oncology, with a strong background in cell-based research and a Doctor of Philosophy in Chemistry from the University of Oregon. With experience as a PhD researcher, Sarah contributed to six publications, including two as the first author, focusing on biological sulfur species and optimizing cell-based assays. Previous roles include research assistant positions at Cal Poly Corporation and California Polytechnic State University, where Sarah assisted in literature retrieval and evaluated student lab reports. Sarah also gained analytical experience through research on algae samples and wastewater testing, and earlier worked at Vacuum Engineering & Materials, managing product data and website content.
This person is not in any teams
ALX Oncology
ALX Oncology is a publicly traded, clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system.